Further Information
BTG is developing BGC20-1531 as a treatment for acute migraine following evidence from pre-clinical profiling, including reversal of PGE2-induced vasodilator responses in the human cerebral vessels in vitro.

In addition, there is extensive evidence supporting the utility of EP4 receptor antagonists in further pain indications and immune diseases. BGC20-1531 has shown statistically significant analgesic effects in both neurogenic and inflammatory pain paradigms in healthy volunteers and data from further non-clinical models supports a broader therapeutic application for this novel compound.

Migraine headache is estimated to affect 10-20% of the world population and is listed by the World Health Organisation in the top 20 causes of disabling conditions, and in the top four neurological disabling conditions. The most common current therapies for acute migraine are non-steroidal anti-inflammatory drugs (NSAIDs) and triptans. However, many migraine sufferers do not experience sufficient relief from these treatments or cannot tolerate gastrointestinal, cardiovascular and other side-effects.

BTG is actively looking for partners for BGC20-1531.

Please contact our Business Development Team for more information.